Stock Analiz

20/20 Biolabs, Inc. AIDX

Precision Instruments · data as of November 13, 2026

$0.20Market cap $3M
Open the interactive analysis →

20/20 Biolabs, Inc. (AIDX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $2M and net income of -$6M, a net margin of -285.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -278%.

About 20/20 Biolabs

20/20 Biolabs is listed in the US and classified in precision instruments. It was profitable in 0 of the last 2 years in our data. It spends 29% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.3
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-102.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)16.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-249.8%
ROIC (5-yr avg.)-278.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal yearTTM20252024
Revenue$2M$2M$2M
Net income-$6M-$4M-$6M
Free cash flow-$3M-$2M-$3M
EPS (diluted)$-0.97$-0.76$-1.16
Net margin-285.0%-182.8%-316.8%
ROIC—-365.4%-191.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does 20/20 Biolabs pay a dividend?

Not currently.

Is 20/20 Biolabs a good stock to buy?

We do not give buy or sell advice. 20/20 Biolabs scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.